GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » EV-to-EBIT

MAIA Biotechnology (MAIA Biotechnology) EV-to-EBIT : -3.43 (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MAIA Biotechnology's Enterprise Value is $81.47 Mil. MAIA Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.72 Mil. Therefore, MAIA Biotechnology's EV-to-EBIT for today is -3.43.

The historical rank and industry rank for MAIA Biotechnology's EV-to-EBIT or its related term are showing as below:

MAIA' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.38   Med: 0   Max: 0
Current: -3.43

MAIA's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs MAIA: -3.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MAIA Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 was $37.01 Mil. MAIA Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.72 Mil. MAIA Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -64.10%.


MAIA Biotechnology EV-to-EBIT Historical Data

The historical data trend for MAIA Biotechnology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology EV-to-EBIT Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -1.74 -0.64

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 -1.18 -1.37 -0.64 -1.56

Competitive Comparison of MAIA Biotechnology's EV-to-EBIT

For the Biotechnology subindustry, MAIA Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAIA Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's EV-to-EBIT falls into.



MAIA Biotechnology EV-to-EBIT Calculation

MAIA Biotechnology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=81.471/-23.722
=-3.43

MAIA Biotechnology's current Enterprise Value is $81.47 Mil.
MAIA Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAIA Biotechnology  (AMEX:MAIA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MAIA Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-23.722/37.0083
=-64.10 %

MAIA Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 was $37.01 Mil.
MAIA Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAIA Biotechnology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology (MAIA Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606